Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Hematologic Diseases 1

Interventions

Carboplatin 27pembrolizumab 26Cisplatin 24Paclitaxel 21Nivolumab 19Gemcitabine 16Pemetrexed 14Rituximab 14Ipilimumab 12Cyclophosphamide 11Dexamethasone 11Fluorouracil 10Capecitabine 9Docetaxel 9durvalumab 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5Ado-Trastuzumab Emtansine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × idelalisib × 1 year × Clear all
NCT02970318 2026-05-11

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Acerta Pharma BV

Phase 3 Active not recruiting
310 enrolled 18 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04666038 2026-04-24

BRUIN CLL-321

Eli Lilly and Company

Phase 3 Active not recruiting
238 enrolled 17 charts 1 FDA
LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡